View highlights and coverage from leading international Neurology congresses
It was a great pleasure to meet with Michael Weiner (University of California, San Francisco, CA, USA), the Principal Investigator for the Alzheimer’s Disease Neuroimaging Initiative (ADNI), to discuss the initiative’s aims, design and future developments. The abstract entitled ‘Validating Plasma Tests for Amyloid, Tau, and Neurodegeneration Using the Alzheimer’s Disease Neuroimaging Initiative (ADNI)’ was […]
It was a great pleasure to speak with Stephen Pasternak (University of Western Ontario, Ontario, Canada) to discuss the phase 2 trial investigating ambroxol as a disease-modifying treatment for Parkinson’s Disease dementia. The abstract entitled ‘Ambroxol as a Disease-modifying Treatment for Parkinson’s Disease Dementia: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial’ was presented at The […]
It was a great pleasure to speak with Stephen Pasternak (University of Western Ontario, Ontario, Canada) to discuss ambroxol as a disease-modifying treatment for Parkinson’s Disease dementia. The abstract entitled ‘Ambroxol as a Disease-modifying Treatment for Parkinson’s Disease Dementia: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial’ was presented at The 15th International Conference for Alzheimer’s […]
TouchNEUROLOGY had the great pleasure of speaking with Marwan Sabbagh (Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA) to discuss the phase 2 MCLENA-1 clinical trial rationale, assessing lenalidomide in patients with mild cognitive impairment due to Alzheimer’s Disease. The abstract entitled ‘Rationale for the MCLENA-1: A Phase II Clinical Trial for the Assessment […]
We had the pleasure of speaking with Tanya Simuni (Northwestern University Feinberg School of Medicine, Chicago, IL, USA) to discuss the use of venglustat in the treatment of patients with Parkinson’s Disease, and the Phase 2 MOVES-PD study results. Part 1 of our discussion can be viewed here. The abstract entitled ‘Venglustat in Parkinson’s Disease […]
We caught up with Tanya Simuni (Northwestern University Feinberg School of Medicine, Chicago, IL, USA) to discuss the use of venglustat in the treatment of patients with Parkinson’s Disease, and the Phase 2 MOVES-PD study results. Part 2 of our discussion can be viewed here. The abstract entitled ‘Venglustat in Parkinson’s Disease Patients with a […]
We had the pleasure of meeting with Yona Levites (Center for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL, USA) to discuss immunotherapeutic approaches in Alzheimer’s Disease. Part 2 of the discussion can be viewed here. The abstract entitled ‘Immunotherapeutic approaches in Alzheimer’s Disease’ was presented at The 15th International Conference for Alzheimer’s […]
We had the pleasure of meeting with Yona Levites (Center for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL, USA ) to discuss her phase 1 study investigating the scFv-CD protein as a framework for identifying an optimized immunotherapy for Alzheimer’s Disease, and potentially other neurodegenerative disorders. Part 1 of the discussion can […]
touchNEUROLOGY had the pleasure of meeting with Tobias Hartmann (Director and Professor of Experimental Neurology, DIDP, Saarland University, Saarbrücken, Germany) to discuss the recent post-hoc analysis of the LipiDiDiet trial data. Part 1 of our discussion can be found here. The abstract entitled ‘ADCOMS: A Post-Hoc Analysis Using Data from the 3-Year Lipididiet Trial in […]
Get the latest clinical insights from touchNEUROLOGY
